港股異動丨小米一度升6%創逾3年新高,消息稱第二款車型計劃明年2、3月上市
小米集團-W(1810.HK)上午盤中一度升6%,報29.85港元,股價創2021年6月以來新高,截至半日收盤升3.2%報29.05港元。消息面上,小米汽車內部人士透露:“小米第二款車型計劃於明年2、3月上市。”這與小米集團創始人、董事長雷軍此前透露的“小米SU7 Ultra量產版將於2025年3月正式發佈”的信息,在時間上不謀而合。 另一位接近小米汽車的消息人士表示,小米第二款新車的上市安排將與此前SU7上市節奏一致。而SU7的上市時間恰好是2024年3月28日。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.